Sanofi

The @US_FDA has granted breakthrough therapy designation to our investigational treatment for type 3 Gaucher disease (GD3). Learn more: sanofi.com/en/media-room/…

The European Medicines Agency's CHMP has recommended the approval of our medicine in the EU to treat chronic spontaneous urticaria (CSU) in certain children aged 2 to 11 years. ️ Learn more: sanofi.com/en/media-room/… CC: @Regeneron

Together with @DNDi and FoundationS, we’re proud to receive a positive CHMP (Committee for Medicinal Products for Human Use) opinion from the European Medicines Agency for our new treatment for adults and adolescents with early and advanced stage gambiense sleeping sickness. This recommendation paves the way to bring innovative treatment to people affected by this deadly disease and aligns with the World Health Organization’s goal of eliminating gambiense sleeping sickness by 2030. We remain committed to advancing scientific innovation to address unmet patient needs, particularly vulnerable communities. Read our press release ➡️ spkl.io/6019AauOV #ActForPatients #FoundationS #DNDi #GlobalHealth #SleepingSickness

The @US_FDA has approved our medicine for allergic fungal rhinosinusitis (AFRS) in certain adults and children. Learn more about this milestone: sanofi.com/en/media-room/… CC: @Regeneron

New phase 2b maintenance results evaluating an investigational treatment for ulcerative colitis and Crohn’s disease, highlighting our commitment to scientific innovation for patients with inflammatory bowel disease. Read our press release. sanofi.com/en/media-room/…

GVHD is a serious complication affecting up to 1 in 2 patients who undergo a stem cell transplant. Today, February 17, marks #GVHDDay - an opportunity to recognize and empower those living this devastating disease. Learn more ➡️ spkl.io/6018AQnpp #ProtectingThePromise #GVHD

New NIRSE-GAL study, published in The Lancet Infectious Diseases and presented at Respiratory Syncytial Virus (#RSV) Vaccine for the World conference, shows public health outcomes with an infant RSV immunization program across two seasons. Read our press release ➡️ spkl.io/6014AQJZm

We're pleased to announce that we have completed the acquisition of @DynavaxCorp This strengthens our presence in adult immunization by bringing together Dynavax's vaccines with Sanofi's commercial reach, global scale and development capabilities. Read our press release ➡️ spkl.io/6016AtMRM

Our investigational BTK inhibitor for the potential treatment of wAIHA was granted Breakthrough Therapy Designation by @US_FDA and Orphan Drug by @MHLWitter_en in Japan, validating our commitment to helping address unmet needs for people living with rare diseases. Learn more: sanofi.com/en/media-room/…

New results from two phase 3 studies of our investigational oral therapy in type 3 Gaucher disease and Fabry disease are now available. Learn more about this #RareDisease research. sanofi.com/en/media-room/…

Hi @AadiAkhilesh , we take product complaints seriously and have reported your concern to our product quality team. Could you send us a DM with your contact details so they can reach out for more info? If you have other health-related questions, please talk to your healthcare provider.

@IndiaSanofi dear sir I have taken a product Lantus Solostar pen for a diabetes patient. I have raised a complaint against the same as its not working properly. Inspite of 1 week I didn't get any solution from company side even toll free no is not reachable. @sanofi

The @EMA_News CHMP has recommended the approval of our therapy to treat patients aged 12+ with chronic graft-vs-host disease cGVHD, a life-threatening complication that affects up to 1 in 2 people who undergo a stem cell transplant. Learn more ➡️ spkl.io/6013ASKDU

Our Q4 and full-year 2025 results are now available. Learn more: spkl.io/6016AqNnO #SanofiResults $SAN $SNY

#NEWS: New data confirms potential in #AtopicDermatitis These results demonstrate the potential of OX40-ligand as an important #NEW mechanism in #AD. Learn more: spkl.io/6012AUQKa #Dermatology #ClinicalResearch #Innovation

#NEWS: The National Medical Products Administration in China has approved treatments for obstructive hypertrophic cardiomyopathy (oHCM), and familial chylomicronaemia syndrome (FCS). Learn more ➡️ spkl.io/6017AoHXz

#NEWS: The @EU_Commission has approved our medicine to delay the onset of stage 3 type 1 diabetes in patients aged eight years and older with stage 2 #T1D marking the first disease-modifying treatment option in the EU for early T1D. Learn more: spkl.io/6010AWkLy

The @US_FDA accepted for Priority Review our sBLA for children between one and eight years of age with stage 2 #Type1Diabetes. Learn more about this milestone ➡️ spkl.io/6017AmEPt

#NEWS: We've entered into an agreement to acquire @DynavaxCorp, adding an adult hepatitis B vaccine and shingles candidate to our adult #vaccine portfolio and pipeline. Learn more➡️sanofi.com/en/media-room/…

Update on the @FDA review of our investigational treatment in non-relapsing secondary progressive multiple sclerosis (nrSPMS). Read our press release: sanofi.com/en/media-room/…

#NEWS: The @EU_Commission has approved the first BTK inhibitor to treat adults with immune thrombocytopenia (#ITP) who are refractory to other treatments. Learn more: spkl.io/6012AYTR0